← All trials
NCT00421538
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- May 1, 2015
- Completion date
- Sep 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of GenevaLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of OttawaOverall official - principal investigator
- University of GenevaOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- Swiss National Science FoundationCollaborator
- University of GenevaReponsible party - principal investigator
- Government of FranceCollaborator
- McGill UniversityOverall official - principal investigator
- Technion UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.